Vuilleumier N, Montecucco F, Hartley O. Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol 2014; 6(5): 314-326 [PMID: 24944761 DOI: 10.4330/wjc.v6.i5.314]
Corresponding Author of This Article
Dr. Nicolas Vuilleumier, MD, PD, Head of Laboratory Medicine Division, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. nicolas.vuilleumier@hcuge.ch
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. May 26, 2014; 6(5): 314-326 Published online May 26, 2014. doi: 10.4330/wjc.v6.i5.314
Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity
Nicolas Vuilleumier, Fabrizio Montecucco, Oliver Hartley
Nicolas Vuilleumier, Fabrizio Montecucco, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland
Nicolas Vuilleumier, Fabrizio Montecucco, Department of Human Protein Sciences, Faculty of Medicine, 1211 Geneva, Switzerland
Fabrizio Montecucco, Department of Internal Medicine, Foundation for Medical Researches, Faculty of Medicine, Geneva 1211, Switzerland
Oliver Hartley, Department of Immunology and Pathology, Faculty of Medicine, 1211 Geneva, Switzerland
Author contributions: All the authors contributed to this manuscript.
Supported by Swiss National Science Foundation Grants to Dr. Vuilleumier N No. 310030_140736; and to Dr. Montecucco F No. 32003B_134963/1; a grant from the Foundation “Gustave and Simone Prévot” to Dr. Montecucco F
Correspondence to: Dr. Nicolas Vuilleumier, MD, PD, Head of Laboratory Medicine Division, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. nicolas.vuilleumier@hcuge.ch
Telephone: +41-22-3729150 Fax: +41-22-3827245
Received: December 23, 2013 Revised: February 5, 2014 Accepted: March 17, 2014 Published online: May 26, 2014 Processing time: 178 Days and 19.6 Hours
Core Tip
Core tip: This review provides a comprehensive and critical analysis of the most recent basic research articles and clinical trials on the role of autoantibodies to apolipoprotein A-1 as biomarkers and potential mediators of cardiovascular diseases (CVD). Evidence from both in vitro and in vivo studies showed that anti-apolipoprotein A-1 IgG might have critical pro-atherosclerotic activities by activating immune cells to release pro-inflammatory mediators and proteases. In addition, these autoantibodies might increase heart rate and arrhythmias both in humans and animal models. These studies suggest a causal role of anti-apolipoprotein A-1 immunoglobulins of G class in CVD, indicating that those autoantibodies could potentially represent an emerging therapeutic target to better fight CVD.
